机译:Vedolizumab治疗炎症肠病的严重脊椎病相关enthishathy的出现
Univ Leeds Leeds Inst Rheumat &
Musculoskeletal Med Leeds W Yorkshire England;
East Hertfordshire NHS Trust Stevenage Herts England;
Sacro Cuore Don Calabria Hosp Negrar Italy;
Univ Toronto Mt Sinai Hosp Toronto ON Canada;
Univ Toronto Mt Sinai Hosp Toronto ON Canada;
Univ Toronto Mt Sinai Hosp Toronto ON Canada;
Univ Hosp Ile de France Hop Lariboisiere APHP Paris France;
Sorbonne Paris Cite Univ Hop St Louis APHP Paris France;
Sorbonne Paris Cite Univ Hop St Louis APHP Paris France;
Royal Free Hosp London England;
Univ Palermo Palermo Italy;
Leeds Teaching Hosp NHS Trust Leeds W Yorkshire England;
Leeds Inst Rheumat &
Musculoskeletal Med Leeds W Yorkshire England;
Univ Leeds Leeds Inst Rheumat &
Musculoskeletal Med Leeds W Yorkshire England;
Univ Leeds Leeds Inst Rheumat &
Musculoskeletal Med Leeds W Yorkshire England;
机译:Vedolizumab治疗炎症肠病的严重脊椎病相关enthishathy的出现
机译:成功伏沙尔替之疗法治疗炎症性肠病后,严重脊椎病相关患有患有的出现
机译:评论:在炎症性肠病成功vedolizumab治疗后,患有严重脊椎病相关患者病理的出现
机译:用于调节肠道先天免疫系统的部位定向聚合物 - 药物复合物,以预防/治疗炎症性肠病(IBD)
机译:特定碳水化合物饮食治疗活性,严重,生物难治性炎症肠病患者的疗效
机译:vedolizumab诱导临床反应和疗效的功效中度至重度炎症性肠病患者缓解至少两种TNF拮抗剂治疗失败
机译:炎症性肠道病成功vedolizumab治疗后,严重脊椎病有关的肌腱病理的出现